Palivizumab is a monoclonal antibody directed against RSV surface fusion protein .
However , palivizumab ( brand name Synagis manufactured by MedImmune ) , a moderately effective prophylactic drug , is available for infants at high risk .
brand name is a monoclonal brand name directed against RSV surface fusion protein .
However , palivizumab ( brand name Synagis manufactured by MedImmune ) , a moderately effective prophylactic drug , is available for infants at high risk .